Lymphoma: A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory
Mantle Cell Lymphoma (ZUMA-2)
Is KTE-C19 safe and effective in treating your lymphoma when administered after a
3 day course of chemotherapy?
Basic Study Information
Purpose:Location: Cancer Center
The sponsor is testing an experimental treatment named KTE-C19, which uses the patient’s
own genetically altered blood cells to treat cancer. KTE-C19 is made from blood cells
that are removed from the patient. A virus (retrovirus) is used to introduce a gene
that creates a protein (called a chimeric antigen receptor or CAR) on the surface
of T cells, a type of blood cell that fights infection and eliminates cancer cells.
The hope is that the CAR on the T cells will bind to and kill cells that express CD19,
a molecule that is found on B-cell lymphomas.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02601313?term=Kite+102&rank=1
Study Reference #: ILYM-15080
Lead Researcher (Principal Investigator)
Lead Researcher: Patrick Reagan
Study Contact InformationStudy Coordinator: Erin Enfield
Phone: (585) 276-4404
Additional Study Details
Learn More About These Conditions
More information about Lymphoma, Mantle-Cell
More information about Mantle cell lymphoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search